<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-76432</identifier>
<setSpec>0304-5013</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Hypertension and the transdermal contraceptive patch</dc:title>
<dc:description xml:lang="en">Cardiovascular complications are one of the risks of hormonal contraception use (a two-fold risk of stroke and ischemic infarct and a four-fold risk of thromboembolic complications). Although the development of hypertension is infrequent, cases of accelerated hypertension accompanied by renal failure have been described. This adverse effect has been reported in relation to oral contraceptives but there are no references in the literature to the use of transdermal contraceptives, despite differences in the pharmacodynamics between the two routes of administration. We report the case of a 22-year-old woman who developed malignant hypertension with renal failure after replacing oral contraceptives for the transdermal patch. The hypertension resolved after discontinuing transdermal contraceptive use. Further studies are required to clarify this possible association but this isolated case highlights the importance of blood pressure measurement in the monitoring of hormonal contraception users (AU)</dc:description>
<dc:creator>Beiro Felipe, Eva</dc:creator>
<dc:creator>Fernández Mellado, M. José</dc:creator>
<dc:creator>González Peña, Ola</dc:creator>
<dc:creator>López Valverde, Miguel</dc:creator>
<dc:creator>Cruz Quílez Conde, José</dc:creator>
<dc:creator>Mozo De Rosales Fano, Fernando</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Entre las complicaciones de la anticoncepción hormonal destacan las cardiovasculares (doble riesgo de accidente cerebrovascular e infarto isquémico, y riesgo cuatro veces mayor de presentar complicaciones tromboembólicas). A pesar de que la aparición de hipertensión arterial (HTA) es poco frecuente, se han descrito casos de HTA acelerada acompañada de daño renal. Este efecto adverso se ha documentado en relación con los anticonceptivos orales y no se han encontrado en la literatura científica referencias al uso de anticonceptivos transdérmicos pese a la diferencia en su farmacodinamia. Presentamos el caso clínico de una paciente de 22 años que desarrolló HTA maligna con fallo renal tras sustituir anticonceptivos orales por vía transdérmica y que cedió al detener el tratamiento. Son necesarios más estudios para aclarar esta posible relación, pero este hecho aislado remarca la importancia de la recomendación sobre la toma de presión arterial como parámetro de control clínico de las usuarias de anticoncepción hormonal (AU)</dc:description>
<dc:source>Prog. obstet. ginecol. (Ed. impr.);53(2): 59-61, feb. 2010.</dc:source>
<dc:identifier>ibc-76432</dc:identifier>
<dc:title xml:lang="es">Hipertensión arterial y anovulatorios transdérmicos</dc:title>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d3292^s22020</dc:subject>
<dc:subject>^d3292^s22074</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d7152^s22012</dc:subject>
<dc:subject>^d33405^s22073</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d3289^s22073</dc:subject>
<dc:subject>^d3289^s22078</dc:subject>
<dc:subject>^d7152^s22057</dc:subject>
<dc:subject>^d3293^s22074</dc:subject>
<dc:subject>^d32748^s22074</dc:subject>
<dc:subject>^d30857^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201002</dc:date>
</metadata>
</record>
</ibecs-document>
